http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011119345-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 |
| filingDate | 2011-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011119345-A |
| titleOfInvention | METHODS OF APPLICATION (+) 1,4-DIHYDRO-7 - [(3S, 4S) -3-METOXY-4- (METHYLAMINO) -1-PYROLIDINYL] -4-OXO-1- (2-THIAZOLYL) -1.8 -Naphthyridine-3-Carboxylic Acid For Cancer Treatment |
| abstract | 1. A method for treating leukemia, comprising administering to a person from about 10 to about 90 mg / m2 enantiomerically pure (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1 -pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid, where the leukemia is chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia or acute myelogenous leukemia. ! 2. The method according to claim 1, where the leukemia is acute lymphoblastic leukemia. ! 3. The method according to claim 2, where acute lymphoblastic leukemia occurs from blast cells of bone marrow, thymus, or lymph nodes. ! 4. The method according to claim 3, where acute lymphoblastic leukemia is a T-cell leukemia. ! 5. The method according to claim 4, where T-cell leukemia is peripheral T-cell leukemia, T-cell lymphoblastic leukemia, cutaneous T-cell leukemia or adult T-cell leukemia. ! 6. The method according to claim 1, where the leukemia is acute myelogenous leukemia. ! 7. The method according to claim 1, where the acute myelogenous leukemia is myeloid leukemia or promyelocytic leukemia. ! 8. The method according to claim 1, where the leukemia is recurrent, refractory or resistant to conventional treatment. !9. The method according to claim 1, where the dose is from about 15 to about 80 mg / m2. ! 10. The method according to claim 1, where the dose is from about 50 mg / m2 to about 80 mg / m2, which is administered once a week. ! 11. The method according to claim 10, where the dose is from about 55 mg / m2 to about 75 mg / m2. ! 12. The method according to claim 11, where the dose is approximately 60 mg / m2. ! 13. The method according to claim 11, where the dose is approximately 65 mg / m2. ! 14. The method according to claim 11, where the dose is about 70 mg / m2. ! 15. The method according to claim 11, where the dose is about 75 mg / m2. ! 16. The method according to claim 9, where the dose |
| priorityDate | 2005-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.